A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Rix, Uwe, Colinge, Jacques, Blatt, Katharina, Gridling, Manuela, Remsing Rix, Lily L., Parapatics, Katja, Cerny-Reiterer, Sabine, Burkard, Thomas R., Jäger, Ulrich, Melo, Junia V., Bennett, Keiryn L., Valent, Peter, Superti-Furga, Giulio
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3795025/
https://ncbi.nlm.nih.gov/pubmed/24130846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0077155
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki